RIGEL PHARMACEUTICALS INC secured exclusive global rights to a breast cancer drug from PFIZER INC and ARVINAS INC on May 12. The deal adds a fourth commercial product to Rigel's portfolio and sent its shares up over 5% in premarket trading. The expansion into advanced breast cancer treatments diversifies Rigel's revenue stream beyond its existing niche therapies.
Rigel Licenses Pfizer and Arvinas Cancer Drug Veppanu
Rigel Pharmaceuticals has secured global rights to the breast cancer drug Veppanu from Pfizer and Arvinas. The deal includes a $70 million upfront payment.
Xurve View
Insights:
Xurve View
### Terms of the Veppanu Acquisition Rigel will pay $70 million upfront for the rights to develop, manufacture, and commercialize Veppanu. An additional $15 million is due upon the completion of transition activities. Pfizer and Arvinas remain eligible for up to $320 million in future regulatory and commercial milestones plus sales royalties.











